Active Ingredient History
CLOBETASOL, a derivative of prednisolone with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than fluocinonide, it is used topically in the treatment of psoriasis but may cause marked adrenocortical suppression. For short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. Like other topical corticosteroids, clobetasol has anti-inflammatory, antipruritic, and vasoconstrictive properties. It is a very high potency topical corticosteroid that should not be used with occlusive dressings. Topical corticosteroids share anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of topical steroids is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Initially, however, clobetasol, like other corticosteroids, bind to the glucocorticoid receptor, which complexes, enters the cell nucleus and modifies genetic transcription (transrepression/transactivation). NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alopecia (Phase 4)
Alopecia Areata (Phase 4)
Arthritis, Rheumatoid (Phase 3)
Blood Vessels (Phase 3)
Cataract (Phase 3)
Cicatrix, Hypertrophic (Phase 4)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Connective Tissue Diseases (Phase 1)
Cyclosteroids (Phase 3)
Dermatitis, Atopic (Phase 3)
Dermatitis, Contact (Phase 4)
Dermatitis, Occupational (Phase 4)
Dermatitis, Seborrheic (Phase 3)
Dermatology (Phase 4)
Eczema (Phase 3)
Graft vs Host Disease (Phase 3)
Hand Dermatoses (Phase 4)
Healthy Volunteers (Phase 1)
Herpes Labialis (Phase 2)
Lichen Planus (Phase 2/Phase 3)
Lichen Planus, Oral (Phase 2/Phase 3)
Lichen Sclerosus et Atrophicus (Phase 3)
Mosquito Vectors (Phase 4)
Neoplasms (Phase 1)
Oral Manifestations (Phase 3)
Pain (Phase 3)
Pemphigoid, Bullous (Phase 4)
Phlebitis (Phase 1/Phase 2)
Psoriasis ()
Scleroderma, Systemic (Phase 1)
Skin and Connective Tissue Diseases (Phase 1)
Stevens-Johnson Syndrome (Phase 1/Phase 2)
Ulcer (Phase 1)
Vasoconstriction (Phase 1)
Vulvar Lichen Sclerosus (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
